![Early Assessment of Masses, Lesions Encouraged by Duke Sarcoma Team | Duke Health Referring Physicians Early Assessment of Masses, Lesions Encouraged by Duke Sarcoma Team | Duke Health Referring Physicians](https://physicians.dukehealth.org/sites/default/files/article/MC-2040%20Images%20for%20CPT%20186%20Orthopaedics.png)
Early Assessment of Masses, Lesions Encouraged by Duke Sarcoma Team | Duke Health Referring Physicians
![New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for](https://ars.els-cdn.com/content/image/1-s2.0-S0959804922004312-gr1.jpg)
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for
![Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets | Nature Communications Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-30453-x/MediaObjects/41467_2022_30453_Fig1_HTML.png)
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets | Nature Communications
![The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-018-5163-2/MediaObjects/12885_2018_5163_Fig2_HTML.png)
The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text
![NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma | National Institutes of Health (NIH) NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma | National Institutes of Health (NIH)](https://irp.nih.gov/sites/default/files/media/image/2023-02/news-12-28-2022-NIH_clinical_trial_atezolizumab_shrunk.png)
NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma | National Institutes of Health (NIH)
![Patients with a rare and aggressive form of liposarcoma need treatment advances | Boehringer Ingelheim US Patients with a rare and aggressive form of liposarcoma need treatment advances | Boehringer Ingelheim US](https://www.boehringer-ingelheim.com/us/sites/default/files/2022-11/786212590_bi_sarcoma-alliance_quotegreens.jpg)
Patients with a rare and aggressive form of liposarcoma need treatment advances | Boehringer Ingelheim US
![Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/244642bf-33f8-469a-a9ca-0d7de2d9cdb6/gr1_lrg.gif)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology
![Cancers | Free Full-Text | IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers Cancers | Free Full-Text | IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers](https://www.mdpi.com/cancers/cancers-12-01768/article_deploy/html/images/cancers-12-01768-g001.png)
Cancers | Free Full-Text | IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers
![GlobalData's clinical trial report, “Ewing Sarcoma - Global Clinical Trials Review, H2, 2021" provides an overview of Ewing Sarcoma Clinical trials scenario. This report provides top line data relating to the clinical GlobalData's clinical trial report, “Ewing Sarcoma - Global Clinical Trials Review, H2, 2021" provides an overview of Ewing Sarcoma Clinical trials scenario. This report provides top line data relating to the clinical](https://www.globaldata.com/store/wp-content/uploads/sites/2/2021/09/Ewing-Sarcoma-Clinical-Trials-Market-by-G7-Countries-1024x493.png)
GlobalData's clinical trial report, “Ewing Sarcoma - Global Clinical Trials Review, H2, 2021" provides an overview of Ewing Sarcoma Clinical trials scenario. This report provides top line data relating to the clinical
![Published clinical trials in sarcoma and TIM histotypes. The histograms... | Download Scientific Diagram Published clinical trials in sarcoma and TIM histotypes. The histograms... | Download Scientific Diagram](https://www.researchgate.net/publication/349614101/figure/fig1/AS:998403437781002@1615049337778/Published-clinical-trials-in-sarcoma-and-TIM-histotypes-The-histograms-present-the.png)